Tag: plasma

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA¹ 

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces today that further to its news release dated May 28, 2025, and further to today’s press release from PyroGenesis’ client HPQ Silicon Inc. (“HPQ”), HPQ Silica Polvere Inc. (“Polvere”) has received notice from a leading global supplier of fumed silica that the material samples recently delivered to them have successfully passed the client’s test protocols for being confirmed as fumed silica. As previously announced, these samples were produced by the Fumed Silica Reactor (the “FSR”) pilot plant, which PyroGenesis has been engaged to develop and build for Polvere, a subsidiary of HPQ.

Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers